

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 7/48		A1	(11) International Publication Number: WO 00/56279 (43) International Publication Date: 28 September 2000 (28.09.00)
(21) International Application Number:	PCT/IB00/00278	(81) Designated States:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	14 March 2000 (14.03.00)	(30) Priority Data:	60/125,553 22 March 1999 (22.03.99) US
(71) Applicant (for all designated States except US):	PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).	(72) Inventor; and	
(75) Inventor/Applicant (for US only):	COLLINGTON, Eric, William [GB/GB]; Birch House, 28 Watton Road, Knebworth, Hertfordshire SG3 6AH (GB).	(74) Agents:	SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(54) Title: RESORCINOL COMPOSITION

(57) Abstract

The present invention relates to the use of a resorcinol derivative as a skin lightening agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RESORCINOL COMPOSITION

The present invention relates to the use of a resorcinol derivative, *i.e.*, 4-(2,4-dihydroxyphenyl)cyclohexanol, as a skin lightening agent.

The terms "lightening agent" and "depigmentation agent" are used interchangeably 5 throughout this document.

Skin color in humans arises from a complex series of cellular processes that are carried out within a unique population of cells called melanocytes. Melanocytes are located in the lower part of the epidermis, and their function is to synthesize a pigment, melanin, which protects the body from the damaging effects of ultraviolet radiation.

10 When skin is exposed to ultraviolet radiation, such as that contained in sunlight, melanocytes increase their synthesis of melanin. Melanin is deposited in melanosomes, which are vesicles found within the cell. The melanosomes are extruded from the cell and carried to the surface of the skin by keratinocytes, which internalize the melanin containing melanosomes. The end result is that the visible layers of the skin exhibit a brown color 15 typically known as a "tan". The darkness of the color observed in the skin is proportionate to the amount of melanin synthesized by melanocytes and transferred to the keratinocytes.

The mechanism by which skin pigmentation is formed, *i.e.*, melanogenesis, is particularly complex and schematically involves the following main steps: Tyrosine→L-Dopa→Dopaquinone→Dopachrome→Melanins. The first two reactions in this series are 20 catalyzed by the enzyme tyrosinase. The activity of tyrosinase is promoted by the action of α -melanocyte stimulating hormone or UV rays to have melanin eventually formed as chromatism in the skin. It is well established that a substance has a depigmenting effect if it acts directly on the vitality of the epidermal melanocytes where melanogenesis normally occurs and/or if it interferes with one of the stages in melanin biosynthesis. The active 25 compounds that are employed in the various methods and compositions of this invention inhibit tyrosinase and thus inhibit or decrease melanin biosynthesis.

There is a strong demand for agents that enable acquired deposition sites, such as spots or freckles, to be restored to a normal skin color. For this purpose, a variety of agents and methods have been developed and put on the market. Examples of such methods are (a) 30 a method wherein vitamin C (L-ascorbic acid) having good reducing ability is administered orally in large amounts, (b) a method wherein glutathione is administered parenterally; (c) a method wherein a peroxide, such as hydrogen peroxide, zinc peroxide, sodium peroxide and the like, which is believed to have the bleaching action of melamine, is administered; and (d) a method wherein vitamin C or cysteine is administered topically in the form of an ointment, 35 cream, lotion or the like. Vitamin C has a problem with respect to stability and becomes so

unstable in water-containing systems that they will cause changes in odor and color. Thiol compounds such as glutathione and cysteine do not exhibit a satisfactory depigmental effect since the development of the effect is very slow.

The substances in widest use at the present time as depigmentors are, in particular, 5 hydroquinone and its derivatives, particularly its ethers such as hydroquinone monomethyl ether. These compounds, while effective, are known to produce side effects that can be dangerous. Hydroquinone, use of which is limited to a concentration of 2%, is both irritating and cytotoxic to the melanocyte.

United States Patent 4,526,179 refers to certain hydroquinone fatty esters that have 10 good activity and are less irritating and more stable than hydroquinone.

Japanese Patent Application No. 27909/86 refers to other hydroquinone derivatives that do not have the drawbacks of hydroquinone but that have relatively poor efficacy.

United States Patent 5,449,518 refers to 2,5-dihydroxyphenyl carboxylic acid derivatives as skin depigmentation agents.

15 European Patent Application EP 341,664A1 refers to certain resorcinol derivatives as tyrosinase inhibitors and skin depigmentation agents.


The use of topical depigmentation agents that have good efficacy and are harmless is particularly desirable for treating the following: regional hyperpigmentation caused by 20 melanocytic hyperactivity, such as idiopathic melasma occurring either during pregnancy (mask of pregnancy or chloasma) or secondary to estrogen-progesterone contraception; local hyperpigmentation caused by benign melanocytic hyperactivity and proliferation such as lentigo senilis or liver spots; accidental hyperpigmentation such as postlesional photosensitization and scarring; and certain forms of leukoderma such as vitiligo where, if the injured skin cannot be repigmented, the residual zones of normal skin are depigmented to 25 impart a homogeneous white color to the entire skin.

The compound of formula I, *i.e.*, 4-(2,4-dihydroxyphenyl)cyclohexanol, and its pharmaceutically acceptable salts, which are used in the various methods and compositions of this invention, are useful in the treatment of the foregoing dermatological conditions as well 30 as other dermatological conditions, some of which are referred to later in this document, for which the subject being treated desires, for medicinal or cosmetic purposes, to lighten or reduce the pigmentation of the skin affected by the condition.

4-(2,4-dihydroxyphenyl)cyclohexanol, and its pharmaceutically acceptable salts, are also useful for the treatment of inflammatory disorders such as psoriasis and acne, and for the treatment of dandruff.

Summary of Invention

The invention relates to use of the compound 4-(2,4-dihydroxyphenyl)cyclohexanol, which has the formula:



5

The present invention also relates to use of the pharmaceutically acceptable salts of the compound of formula I.

10 The present invention also relates to a topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising an amount of the compound of formula I or a pharmaceutically acceptable salt thereof that is effective in lightening skin or reducing the pigmentation of skin, and a pharmaceutically acceptable carrier.

15 The present invention also relates to a method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human an amount of the compound of formula I or a pharmaceutically acceptable salt thereof that is effective in lightening skin or reducing the pigmentation of skin.

The present invention also relates to a topical pharmaceutical composition for inhibiting tyrosinase in a human, comprising a tyrosinase-inhibiting effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20 The present invention also relates to a method of inhibiting tyrosinase in a human, comprising administering to said mammal a tyrosinase-inhibiting effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof.

25 The present invention also relates to a topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a tyrosinase-inhibiting effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human a tyrosinase-inhibiting effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof.

5 The present invention also relates to a topical or transdermal pharmaceutical composition for the treatment of an inflammatory disorder such as psoriasis, dermatitis or acne, or dandruff, in a human, comprising an amount of the compound of formula I or a pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.

10 The present invention also relates to a method of treating inflammatory disorders such as psoriasis, dermatitis or acne, or dandruff, in a human, comprising administering to said human an amount of the compound of formula I or a pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition.

15 The present invention also relates to a topical or transdermal pharmaceutical composition for the treatment of an inflammatory disorder such as psoriasis, dermatitis or acne in a human, comprising a tyrosinase-inhibiting effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


20 The present invention also relates to a method of treating inflammatory disorders, such as psoriasis, dermatitis or acne, in a human, comprising administering to said human a tyrosinase-inhibiting effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof.

The compound of formula I, *i.e.*, 4-(2,4-dihydroxyphenyl)cyclohexanol, may exist in different diastereomeric forms. This invention relates to all stereoisomers of 4-(2,4-dihydroxyphenyl)cyclohexanol and mixtures thereof, and to all pharmaceutical compositions and methods of treatment defined above that contain or employ them, respectively.

25 Formula I includes compounds identical to that depicted above but for the fact that one or more hydrogen, carbon or other atoms are replaced by isotopes thereof. Such compounds may be useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.

Detailed Description of the Invention

30 The compound of formula I may be prepared as described in the following reaction scheme and discussion.

SCHEME

Referring to the scheme, compounds of formula (1) can be formed by protecting commercially available 4-bromoresorcinol. A suitable protecting group such as methoxymethyl (MOM) can be introduced by conventional methods that are well known to those skilled in the art. For example, alkylation of 4-bromoresorcinol can occur with two 5 equivalents of methoxymethyl chloride in the presence of diisopropylamine in a halogenated solvent at about 0°C to room temperature.

The compound of formula (2) is well known and commercially available. The compound of formula (3) can be obtained from the reaction of the compound of formula (1) with *n*-butyllithium in the presence of N,N,N',N'-tetramethylethylenediamine in an ethereal 10 solvent, followed by the addition of the compound of formula (2). Dehydration of the compound of formula (3) under standard conditions, e.g., heating the compound of formula (3) at about 110°C in a Dean-Stark apparatus in the presence of camphor sulfonic acid in a suitable solvent (e.g., toluene) yields the compound of formula (4). Hydrogenation under standard conditions, e.g., using hydrogen gas and palladium on charcoal in ethanol yields the 15 compound of formula (5). Deprotection under suitable conditions yields the resorcinol of formula (6). The compound of formula (6) can be further derivatised under standard conditions well known to those skilled in the art to yield the resorcinol derivative of formula I. For example, reduction of the compound of formula (6) with a reducing agent such as sodium borohydride in a suitable solvent such as ethanol at a temperature between 0°C and room 20 temperature yields the compound of formula I.

The compound of formula I is weakly acidic in nature and capable of forming base salts with various pharmaceutically acceptable cations. Examples of such salts include the alkali metal and alkaline earth metal salts and, particularly, the sodium and potassium salts. These salts can be prepared by conventional techniques. The chemical bases that are used 25 as reagents to prepare the pharmaceutically acceptable base salts of this invention are those that form non-toxic base salts with the compound of formula I. Such non-toxic base salts include those derived from such pharmaceutically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compound with an aqueous solution containing the desired 30 pharmaceutically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compound and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum 35 yields of the desired final product.

The compound of formula I, i.e., 4-(2,4-dihydroxyphenyl)cyclohexanol, and its pharmaceutically acceptable salts (hereinafter referred to as "the active compounds used in this invention") are useful in the treatment of disorders of human pigmentation, including solar and simple lentigines (including age/liver spots), melasma/chloasma and postinflammatory 5 hyperpigmentation. Such compounds reduce skin melanin levels by inhibiting the production of melanin, whether the latter is produced constitutively or in response to UV irradiation (such as sun exposure). Thus, the active compounds used in this invention can be used to reduce skin melanin content in non-pathological states so as to induce a lighter skin tone, as desired by the user. They can also be used in combination with skin peeling agents (including glycolic 10 acid or trichloroacetic acid face peels) to lighten skin tone and prevent repigmentation.

The active compounds used in this invention can also be used in combination with sunscreens (UVA or UVB blockers) to prevent repigmentation, to protect against sun or UV-induced skin darkening or to enhance their ability to reduce skin melanin and their skin bleaching action. Such compounds can also be used in combination with retinoic acid or its 15 derivatives or any compounds that interact with retinoic acid receptors and accelerate or enhance the invention's ability to reduce skin melanin and skin bleaching action.

The active compounds used in this invention can also be used in combination with ascorbic acid, its derivatives, and ascorbic acid-based products (such as magnesium ascorbate) or other products with an anti-oxidant mechanism (such as resveratrol) that 20 accelerate or enhance their ability to reduce skin melanin and their skin bleaching action.

This invention relates both to methods of lightening or reducing the pigmentation of skin in which an active compounds used in this invention and one or more of the other active ingredients referred to above are administered together, as part of the same pharmaceutical composition, as well as methods in which they are administered separately as part of an 25 appropriate dose regimen designed to obtain the benefits of the combination therapy. The appropriate dose regimen, the amount of each dose administered, and specific intervals between doses of each active agent will depend upon the specific combination of active agents employed, the condition of the patient being treated, and the nature and severity of the disorder or condition being treated. Such additional active ingredients will generally be administered in 30 amounts less than or equal to those for which they are effective as single topical therapeutic agents. The FDA-approved dosages for such active agents that have received FDA approval for administration to humans are publicly available.

The active compounds used in this invention are generally administered in the form of a pharmaceutical composition comprising the compound together with a pharmaceutically 35 acceptable vehicle or diluent. Such composition is generally formulated in a conventional manner utilizing solid or liquid vehicles or diluents as appropriate for topical administration, in

the form of solutions, gels, creams, jellies, pastes, lotions, ointments, salves and the like. Examples of vehicles for application of the active compounds of this invention include an aqueous or water-alcohol solution, an emulsion of the oil-in-water or water-in-oil type, an emulsified gel, or a two-phase system. Preferably, the compositions according to the 5 invention are in the form of lotions, creams, milks, gels, masks, microspheres or nanospheres, or vesicular dispersions. In the case of vesicular dispersions, the lipids of which the vesicles are made can be of the ionic or nonionic type, or a mixture thereof.

As used herein, a "skin-lightening or pigmentation reducing amount of the compound of formula I", and the like, means an amount or concentration of the compound capable of 10 detectably lightening skin or reducing pigmentation in a human, as determined by any standard assay.

As used herein, a "tyrosinase-inhibiting effective amount of the compound of formula I", and the like, means an amount or concentration of the compound capable of detectably inhibiting tyrosinase activity in a human, as determined by any standard assay.

15 As used herein, an "amount of the compound of formula I capable of treating an inflammatory disorder such as psoriasis, dermatitis or acne, or treating dandruff", and the like, means an amount or concentration of the compound capable of detectably ameliorating, reducing, eliminating, slowing, or preventing the progression of, any symptom or condition associated with or caused by such disorder or condition, in a human, as determined by any 20 standard assay.

In the depigmenting compositions according to the present invention, the concentration of the active compounds used in this invention is generally between 0.01 and 10%, preferably between 0.1 and 10%, relative to the total weight of the composition.

25 The compositions of this invention can optionally also contain a moisturizer, a surfactant, keratolytic, an anti-inflammatory agent, a complexing agent, an antioxidant, a preservative, a fragrance, or a sunscreen, or a combination thereof.

The ability of the active compounds used in this invention to inhibit tyrosinase can be determined using any of the following procedures.

1. Tyrosinase (DOPA oxidase) assay using cell lysate:

30 Human melanoma cell line, SKMEL 188 (licensed from Memorial Sloan-Kettering), is used in the cell lysate assay and the screen. In the assay, compounds and L-dihydroxyphenylalanine (L-DOPA) (100 µg/ml) are incubated with the cell lysates containing human tyrosinase for 8 hr before the plates are read at 405 nm. Potency of the compounds in DOPA oxidase assay is correlated very well with that in tyrosine hydroxylase assay using ³H-tyrosine as a substrate. 4-(2,4-dihydroxyphenyl)cyclohexanol, when tested in this assay, 35 exhibited an IC₅₀ of 0.2 µM.

2. Melanin assay in human primary melanocytes:

Compounds are incubated with human primary melanocytes in the presence of α -melanocyte stimulating hormone (α -MSH) for 2-3 days. Cells are then lysed with sodium hydroxide and sodium dodecyl sulfate (SDS) and melanin signals are read at 405 nm.

5 Alternatively, ^{14}C -DOPA is added to the cells in combination with tyrosinase inhibitors and acid-insoluble ^{14}C -melanin is quantitated by a scintillation counter. IC_{50} reflects the inhibitory potency of the compound in the new melanin synthesis that was stimulated by α -MSH.

3. Tyrosine kinase assay (TK):

TK assays can be performed using purified tyrosine kinases domain of c-met, erb-B2, 10 or IGF-r. A specific antibody against phosphorylated tyrosine residue is used in the assay. Colorimetric signals are generated by horseradish peroxidase, which is conjugated to the antibody.

4. Human skin equivalent model:

15 A mixture of human melanocytes and keratinocytes is grown in an air-liquid interphase. This tissue culture forms a three dimensional structure that histologically and microscopically resembles the human skin epidermis. A test compound is added on top of the cells to mimic topical drug application. After incubation with the compounds (10 μM) for 3 days, the cells are washed extensively and lysed for DOPA oxidase assay.

5. IL-1 assay (Interleukin-1 assay):

20 An IL-1 α ELISA assay (R&D system) can be used to evaluate the effect of the compound on IL-1 secretion in a human skin equivalent model. IL-1 α is a pro-inflammatory cytokine and plays a role in UV-induced skin inflammation.

6. In vivo study:

25 Black or dark brown guinea pigs with homogeneous skin color can be used in this study. A solution of the test compound (5% in ethanol:propylene glycol, 70:30) and the vehicle control are applied to the animals twice daily, 5 days per week for 4-8 weeks. Using this assay, depigmentation of skin by 4-(2,4-dihydroxyphenyl)cyclohexanol was observed.

30 The present invention is illustrated by the following example. It will be understood, however, that the invention is not limited to the specific details of this example. Proton nuclear magnetic resonance spectra (^1H NMR) were measured for solutions in d_6 -DMSO, CDCl_3 or d_4 -MeOH, and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane (TMS). The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet, m, multiplet, b, broad.

35 The following example is illustrative only, and is not intended to limit the scope of the present invention.

EXAMPLESIntermediate 11-3-Di(methoxymethoxy)-4-bromobenzene

An oven-dried 250 mL round-bottomed flask equipped with magnetic stirrer, under an argon atmosphere, was loaded with 4-bromoresorcinol (9.45 g, 50 mmol) and CH_2Cl_2 (50 ml). The stirred suspension was cooled to 0°C, and diisopropylamine (19.1 ml, 110 mmol) was added in one portion *via* syringe. Stirring of the red solution was continued for a further 10 min before methyl chloromethyl ether (10.7 ml, 120 mmol) was added dropwise *via* syringe ensuring the internal temperature did not exceed 10°C. The resulting yellow solution was then allowed to warm to room temperature overnight. Ammonium hydroxide solution (50 mL, 50%) was poured into the reaction vessel and stirring was continued for 1 hr. The mixture was poured into a separating funnel and the phases separated. The aqueous phase was then extracted with CH_2Cl_2 (3x30 ml), and the combined organics washed with brine (20 ml), dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* affording an orange oil. Purification was achieved by flash column chromatography, (SiO_2 , ethyl acetate/petroleum ether, 1:1, v/v), furnishing the title product (10.7 g, 77%) as a pale yellow oil. $\delta_{\text{H}}(\text{CDCl}_3)$ 7.42(1H, d), 6.88(1H, d), 6.64(1H, dd), 5.24(2H, s), 5.15(2H, s), 3.53(3H, s), 3.48(3H, s).

Intermediate 220 1-Hydroxy-1-(2,4-dihydroxyphenyl)bis(methoxy methylether)cyclohexan-4-one ethylene ketal

An oven-dried 250 ml round-bottomed flask, equipped with magnetic stirrer, under an argon atmosphere, was loaded with 4-bromoresorcinol-*bis*(methoxymethyl) ether (2.00 g, 7.2 mmol) and THF (50 mL). *N, N, N', N'*-Tetramethylethylene diamine (2.3 ml, 15.2 mmol) was added in one portion *via* syringe and the stirred solution was cooled to -78°C. *n*-Butyl lithium (9.5 ml, 15.2 mmol, 1.6M in hexane) was added dropwise *via* syringe. The resulting yellow solution was stirred for 1 hr at -78°C, and 1,4-cyclohexanedione monoethylene ketal (1.35 g, 8.7 mmol) was added as a solution in THF (25 ml) slowly *via* syringe. The resulting solution was stirred at -78°C for 1 hr, and then allowed to warm to room temperature overnight. Hydrochloric acid (20 ml, 2M) was added and the reaction mixture stirred vigorously for 15 min. Ethyl acetate (100 ml) was added and the mixture poured into a separating funnel. The phases were separated and the aqueous phase was extracted with ethyl acetate (3x20 ml). The combined organics were washed with brine (20 ml), dried over anhydrous magnesium sulphate, filtered and concentrated affording an orange oil which was purified by flash column chromatography (SiO_2 , ethyl acetate/petroleum ether, 45:55, v/v). The title product (1.42 g, 56%) was isolated as a colourless oil. m/z (ES⁺) 337 ($\text{M} - \text{H}_2\text{O} + \text{H}$)⁺; $\delta_{\text{H}}(\text{CDCl}_3)$ 1.61 –

1.64(2H, m), 2.00 – 2.18(6H, m), 3.44(3H, s), 3.48(3H, s), 3.90 – 3.97(4H, m), 5.11(2H, s), 5.24(2H, s), 6.64(1H, dd), 6.82(1H, d), 7.20(1H, d).

Intermediate 3

5 **1-(2,4-Dihydroxyphenylbis(methoxymethylether)cyclohex-1-en-4-one ethylene ketal**

1-Hydroxy-1-(2,4-dihydroxyphenylbis(methoxymethylether)cyclohexane-4-one ethylene ketal (1.40 g, 3.95 mmol) was placed in a 50 ml round-bottomed flask equipped with magnetic stirrer and a Dean-Stark apparatus. Toluene (30 ml) was added, followed by camphor sulphonic acid (10 mg). The stirred solution was then heated under reflux for 1 hr, 10 cooled, and saturated aqueous sodium bicarbonate solution (10 ml) was added. The mixture was poured into a separating funnel and the phases separated. The aqueous phase was extracted with ethyl acetate (2x15 ml), and the combined organics were washed with brine (15 ml), dried over anhydrous magnesium sulphate, filtered, and then concentrated *in vacuo* yielding an orange oil that was purified by flash column chromatography (SiO₂, ethyl acetate/petroleum ether, 45:55, v/v) to afford the title product (0.94 g) as a colourless oil. δ_H (CDCl₃) 1.84(2H, t), 2.41 – 2.43(2H, m), 2.56 – 2.62(2H, m), 3.47(6H, s), 3.98 – 4.02(4H, m), 5.13(4H, s), 5.58 – 5.63(1H, m), 6.64(1H, dd), 6.78(1H, d), 7.08(1H, d).

Intermediate 4

20 **1-(2,4-Dihydroxyphenylbis(methoxymethyl ether)cyclohexan-4-one ethylene ketal**

1-(2,4-Dihydroxyphenylbis(methoxymethylether)cyclohex-1-en-4-one ethylene ketal (0.950 g, 2.83 mmol) and palladium (200 mg, 10% on carbon) were stirred under an atmosphere of hydrogen for 15 hr. The mixture was then filtered through a plug of Celite, washing with ethyl acetate. The filtrate was evaporated to dryness, affording the title product (0.955 g, 100%) as a colourless oil. δ_H (CDCl₃) 1.67 – 1.87 (8H, m), 2.90 – 2.99(1H, m), 3.46(3H, s), 3.48(3H, s), 3.97(4H, s), 5.12(2H, s), 5.18(2H, s), 6.65(1H, dd), 6.78(1H, d), 7.12(1H, d).

30 **Intermediate 5**
4-(2, 4-Dihydroxyphenyl)cyclohexanone

A round-bottomed flask equipped with magnetic stirrer was loaded with 1-(2, 4-dihydroxyphenylbis(methoxymethylether)cyclohexan-4-one ethylene ketal (1.30 g, 3.9 mmol) and methanol (15 ml). To the resulting stirred solution was added aqueous HCl (15 ml, 1M) in one portion. After stirring for 1 hr at room temperature, the acid was quenched by adding saturated aqueous sodium bicarbonate solution (10 ml). After stirring vigorously for 10 min, 35 the reaction mixture was transferred to a separating funnel, the phases separated, and the aqueous phase extracted with ethyl acetate (3x20 ml). The combined organic phases were washed with brine and the solvent evaporated. To the slightly wet crude product was added

methanol (30 ml) and acidic ion exchange resin (4 g). The resulting mixture was heated under reflux with stirring for 5 hr. Filtering through a plug of Celite, washing with ethyl acetate, followed by removal of solvent *in vacuo*, afforded an orange oil. Purification by flash column chromatography, (SiO₂, ethyl acetate/petroleum ether, 1:1, v/v) furnished the title product as a 5 white powder (0.54 g, 68%). m/z (ES⁻) 411 (2M – 1); δ_H(CD₃OD) 1.94(2H, ddd), 2.16 – 2.23(2H, m), 2.41(2H, dt), 2.62(1H, t), 2.63(1H, t), 6.24(1H, dd), 6.31(1H, d), 6.92(1H, d).

(anti)-4-(2,4-Dihydroxyphenyl)cyclohexanol


4-(2, 4-Dihydroxyphenyl)cyclohexanone (18 mg) was placed in a 25 ml round-bottomed flask equipped with magnetic stirrer. Ethanol (5 ml) was added, followed by sodium 10 borohydride (3.3 mg), and the reaction mixture was stirred for 16 hr. Aqueous HCl (20 ml, 1M), followed by ethyl acetate (20 ml), was added, and the organic phase removed and washed with brine (15 ml), dried over anhydrous magnesium sulphate, filtered, and then concentrated *in vacuo*. The residue was purified by flash column chromatography (SiO₂, ethyl acetate/petroleum ether, 60:40, v/v) to afford the title product (14 mg, 78%) as a white 15 solid. m/z (ES⁻) 267 ((M+60) – 1); δ_H (CD₃OD) 1.38-1.56 (4H, m), 1.85-1.88 (2H, m), 2.04 – 2.07 (2H, m), 2.80 (1H, tt), 3.58 – 3.65 (1H, m), 6.24-6.29 (2H, m), 6.90 (1H, d).

All patents, patent applications, and publications cited above are incorporated herein by reference in their entirety.

The present invention is not to be limited in scope by the specific embodiments 20 described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

WHAT IS CLAIMED IS:


1. A topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising an amount of a compound of formula I



5

or a pharmaceutically acceptable salt thereof, which amount is effective in lightening skin or reducing the pigmentation of skin, and a pharmaceutically acceptable carrier.

2. The composition of claim 1, further comprising a sunscreen.
3. The composition of claim 1, further comprising resveratrol or another active 10 agent that is an anti-oxidant.
4. The composition of claim 1, further comprising retinoic acid or a derivative of retinoic acid.
5. The composition of claim 1, further comprising glycolic acid, trichloroacetic acid or another skin peeling agent.
- 15 6. The composition of claim 1, which is in the form of a water-alcohol solution, an oil-in-water emulsion, a water-in-oil emulsion, an emulsified gel, or a two-phase system.
7. The composition of claim 1, which is in the form of a lotion, cream, milk, gel, jelly, paste, ointment, salve, mask, microspheres, nanospheres, or a vesicular dispersion.
- 20 8. A method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human an amount of a compound of formula I




or a pharmaceutically acceptable salt thereof, which amount is effective in lightening skin or reducing the pigmentation of skin.

9. The method of claim 8, in which the compound of formula I or the pharmaceutically acceptable salt thereof is formulated in a water-alcohol solution, an oil-in-water emulsion, a water-in-oil emulsion, an emulsified gel, or a two-phase system.

10. The method of claim 8, in which the compound of formula I or the pharmaceutically acceptable salt thereof is formulated in a lotion, cream, milk, gel, jelly, paste, ointment, salve, mask, microspheres, nanospheres, or a vesicular dispersion.

10 11. A topical pharmaceutical composition for inhibiting tyrosinase in a human, comprising a tyrosinase-inhibiting effective amount of a compound of formula I




15 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. The composition of claim 11, which is in the form of a water-alcohol solution, an oil-in-water emulsion, a water-in-oil emulsion, an emulsified gel, or a two-phase system.

13. The composition of claim 11, which is in the form of a lotion, cream, milk, gel, jelly, paste, ointment, salve, mask, microspheres, nanospheres, or a vesicular dispersion.

14. A method of inhibiting tyrosinase in a human, comprising administering to said human a tyrosinase-inhibiting effective amount of a compound of formula I




5 or a pharmaceutically acceptable salt thereof.

15. The method of claim 14, in which the compound of formula I or the pharmaceutically acceptable salt thereof is formulated in a water-alcohol solution, an oil-in-water emulsion, a water-in-oil emulsion, an emulsified gel, or a two-phase system.

16. The method of claim 14, in which the compound of formula I or the pharmaceutically acceptable salt thereof is formulated in a lotion, cream, milk, gel, jelly, paste, ointment, salve, mask, microspheres, nanospheres, or a vesicular dispersion.


17. A topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising a tyrosinase-inhibiting effective amount of a compound of formula I



15

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


18. A method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human a tyrosinase-inhibiting effective amount of a compound of formula I



or a pharmaceutically acceptable salt thereof.

19. A topical or transdermal pharmaceutical composition for treating an inflammatory disorder or dandruff in a human, comprising an amount of a compound of formula I


5



or a pharmaceutically acceptable salt thereof, which amount is effective in treating such disorder, and a pharmaceutically acceptable carrier.

10 20. The composition of claim 19, wherein the inflammatory disorder is psoriasis, dermatitis or acne.


21. A method of treating an inflammatory disorder or dandruff in a human, comprising administering to said human an amount of a compound of formula I



or a pharmaceutically acceptable salt thereof, which amount is effective in treating such disorder.

22. The method of claim 21, wherein the inflammatory disorder is psoriasis,
5 dermatitis or acne.


23. A topical or transdermal pharmaceutical composition for treating an inflammatory disorder in a human, comprising a tyrosinase-inhibiting effective amount of a compound of formula I



10 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

24. A method of treating an inflammatory disorder in a human, comprising administering to said human a tyrosinase-inhibiting effective amount of a compound of formula I,

-18-



or a pharmaceutically acceptable salt thereof.

25. The method of claim 24, wherein the inflammatory disorder is psoriasis, dermatitis or acne.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/00278

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP 0 904 774 A (PFIZER PROD INC) 31 March 1999 (1999-03-31) page 3, line 1 – line 23 claims 1,4,7,10,13,16,19-24,27,30,33	1-24
A	PATENT ABSTRACTS OF JAPAN vol. 016, no. 470 (C-0990), 30 September 1992 (1992-09-30) & JP 04 169511 A (POLA CHEM IND INC; OTHERS: 01), 17 June 1992 (1992-06-17) abstract	1,19-25



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

5 June 2000

13/06/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentstaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pelli Wablat, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/00278

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI Section Ch, Week 199307 Derwent Publications Ltd., London, GB; Class D21, AN 1993-055163 XP002087694 & JP 05 004905 A (POLA CHEM IND INC), 14 January 1993 (1993-01-14) abstract</p> <p>— EP 0 341 664 A (KURARAY CO) 15 November 1989 (1989-11-15)</p> <p>—</p>	1-18
A		1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatinal Application No
PCT/IB 00/00278

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
EP 0904774 A	31-03-1999	AU	8994698 A		12-04-1999
		CA	2247748 A		23-03-1999
		WO	9915148 A		01-04-1999
		JP	11152203 A		08-06-1999
JP 04169511 A	17-06-1992	JP	2875374 B		31-03-1999
JP 5004905 A	14-01-1993	NONE			
EP 0341664 A	15-11-1989	DE	68902353 D		10-09-1992
		DE	68902353 T		25-03-1993
		JP	1921849 C		07-04-1995
		JP	2049715 A		20-02-1990
		JP	6051619 B		06-07-1994
		JP	7002643 A		06-01-1995
		US	4959393 A		25-09-1990